Article ISI
HEPATOLOGY  (2020)

An Open-Label, Dose-Escalation Study to Assess the Safety and Efficacy of IL-22 Agonist F-652 in Patients With Alcohol-associated Hepatitis

Arab, Juan P.; Sehrawat, Tejasav S.; Simonetto, Douglas A.; Verma, Vikas K.; Feng, Dechun; Tang, Tom; Dreyer, Kevin; Yan, Xiaoqiang; Daley, William L.; Sanyal, Arun; Chalasani, Naga; Radaeva, Svetlana; Yang, Liu; Vargas, Hugo; Ibacache, Mauricio; et. al.

Abstract

BACKGROUND AND AIMS Interleukin-22 has beneficial effects on inflammation and impaired hepatic regeneration that characterize alcohol-associated hepatitis (AH). F-652 is a recombinant fusion protein of human interleukin-22 and immunoglobulin G2 fragment crystallizable. This study aims to assess the safety and efficacy signals of F-652 in patients with moderate and severe AH.

Más información

Título según WOS: An Open-Label, Dose-Escalation Study to Assess the Safety and Efficacy of IL-22 Agonist F-652 in Patients With Alcohol-associated Hepatitis
Título de la Revista: HEPATOLOGY
Volumen: 72
Número: 2
Editorial: LIPPINCOTT WILLIAMS & WILKINS
Fecha de publicación: 2020
Página de inicio: 441
Página final: 453
DOI:

10.1002/HEP.31046
Notas: ISI